Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Xijing Hospital
Modality
Small molecule
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02221102CT.gov Edoxaban for TIA and Acute Minor Stroke | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ischemic Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Edoxaban (this asset) | Xijing Hospital | P2/3 | B · 57 |
| Aspirin | Xijing Hospital | P4 | BBB |
| Pregabalin | Karolinska Institutet | P4 | BB |
| Urokinase-Type Plasminogen Activator | medac GmbH | P3 | BB |
| Vorapaxar | Merck Sharp & Dohme LLC | P3 | B |
| Tocilizumab | Zhujiang Hospital | P3 | B |
| Physiologic Sodium Chloride Solution | Zhujiang Hospital | P3 | B |
| Auto-Cd34+ Cells | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | P1/2 | CCC |
| Cnto 0007 | Janssen Research & Development, LLC | P1 | CC |
+1 more in the Ischemic Disease cohort
Other indications for Edoxaban
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atrial Fibrillation | — | P4 | A · 83 |
| Intracerebral Hemorrhage | — | P4 | BBB · 78 |
| Atrial Flutter | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Edoxaban in Ischemic Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/edoxaban-ischemic-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →